Associations - KRAS mutation

KRAS mutation KRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	KRAS mutation KRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline	cabozantinib capsule Sensitive: A2 - Guideline
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials	cetuximab Resistant: B - Late Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	trifluridine/tipiracil Sensitive: B - Late Trials	trifluridine/tipiracil Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials	gilteritinib Resistant: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	abemaciclib Sensitive: B - Late Trials	abemaciclib Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	selumetinib Sensitive: B - Late Trials	selumetinib Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	regorafenib Sensitive: B - Late Trials	regorafenib Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: B - Late Trials	erlotinib Resistant: B - Late Trials
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	binimetinib Sensitive: B - Late Trials	binimetinib Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	sorafenib Sensitive: C2 – Inclusion Criteria	sorafenib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	bevacizumab Sensitive: C2 – Inclusion Criteria	bevacizumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	trametinib + TPX-0005 Sensitive: C2 – Inclusion Criteria	trametinib + TPX-0005 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	VS-6766 Sensitive: C2 – Inclusion Criteria	VS-6766 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	CYT 387 Sensitive: C2 – Inclusion Criteria	CYT 387 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	sunitinib Sensitive: C2 – Inclusion Criteria	sunitinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	cetuximab + dasatinib Sensitive: C2 – Inclusion Criteria	cetuximab + dasatinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Melanoma Melanoma	KRAS mutation KRAS mutation	Melanoma Melanoma	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Pancreatic Cancer Pancreatic Cancer	KRAS mutation KRAS mutation	Pancreatic Cancer Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria	avelumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	TVB-2640 Sensitive: C2 – Inclusion Criteria	TVB-2640 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C2 – Inclusion Criteria	binimetinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	KRAS mutation KRAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	selinexor Sensitive: C3 – Early Trials	selinexor Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Childhood B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia	KRAS mutation KRAS mutation	Childhood B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials	GS-9973 Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	BAL3833 Sensitive: C3 – Early Trials	BAL3833 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	BAL3833 Sensitive: C3 – Early Trials	BAL3833 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	CYAD-101 Sensitive: C3 – Early Trials	CYAD-101 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	venetoclax Resistant: C3 – Early Trials	venetoclax Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	LY3009120 Sensitive: C3 – Early Trials	LY3009120 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + palbociclib Sensitive: C3 – Early Trials	venetoclax + palbociclib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trametinib Sensitive: C3 – Early Trials	trametinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Gastric Cancer Gastric Cancer	KRAS mutation KRAS mutation	Gastric Cancer Gastric Cancer	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	KPT-8602 Sensitive: C3 – Early Trials	KPT-8602 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials	venetoclax + midostaurin Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials	venetoclax + gilteritinib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials	venetoclax + sorafenib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	venetoclax + cobimetinib Sensitive: C3 – Early Trials	venetoclax + cobimetinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	cobimetinib + SAR442720 Sensitive: C3 – Early Trials	cobimetinib + SAR442720 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	cetuximab + avelumab Resistant: C3 – Early Trials	cetuximab + avelumab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	VS-6766 Sensitive: C3 – Early Trials	VS-6766 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	VS-6766 Sensitive: C3 – Early Trials	VS-6766 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	BGB-283 Sensitive: C3 – Early Trials	BGB-283 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials	osimertinib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	BGB-283 Sensitive: C3 – Early Trials	BGB-283 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	KRAS mutation KRAS mutation	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ceritinib Resistant: C3 – Early Trials	ceritinib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	X-396 Resistant: C3 – Early Trials	X-396 Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	RGX-202 Sensitive: C3 – Early Trials	RGX-202 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	KRAS mutation KRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	sotorasib Resistant: C3 – Early Trials	sotorasib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	KRAS mutation KRAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials	atezolizumab + cobimetinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	ivosidenib Resistant: C3 – Early Trials	ivosidenib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	CH4987655 Sensitive: C3 – Early Trials	CH4987655 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	panitumumab Resistant: C3 – Early Trials	panitumumab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Oral Cancer Oral Cancer	KRAS mutation KRAS mutation	Oral Cancer Oral Cancer	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	irinotecan + metformin Sensitive: C3 – Early Trials	irinotecan + metformin Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	MEK inhibitor Sensitive: C3 – Early Trials	MEK inhibitor Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	KRAS mutation KRAS mutation	Multiple Myeloma Multiple Myeloma	RAD Sensitive: C3 – Early Trials	RAD Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	TVB-2640 Sensitive: C3 – Early Trials	TVB-2640 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Breast Cancer Breast Cancer	KRAS mutation KRAS mutation	Breast Cancer Breast Cancer	TVB-2640 Sensitive: C3 – Early Trials	TVB-2640 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Solid Tumor Solid Tumor	KRAS mutation KRAS mutation	Solid Tumor Solid Tumor	selumetinib Resistant: C3 – Early Trials	selumetinib Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Biliary Tract Cancer Biliary Tract Cancer	KRAS mutation KRAS mutation	Biliary Tract Cancer Biliary Tract Cancer	toripalimab Resistant: C3 – Early Trials	toripalimab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	pembrolizumab + selinexor Sensitive: C3 – Early Trials	pembrolizumab + selinexor Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials	durvalumab Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS inhibitor Resistant: C3 – Early Trials	KRAS inhibitor Resistant: C3 – Early Trials
KRAS mutation KRAS mutation	Juvenile Myelomonocytic Leukemia Juvenile Myelomonocytic Leukemia	KRAS mutation KRAS mutation	Juvenile Myelomonocytic Leukemia Juvenile Myelomonocytic Leukemia	decitabine Sensitive: C4 – Case Studies	decitabine Sensitive: C4 – Case Studies
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	SNR1611 + zoledronic acid Sensitive: C4 – Case Studies	SNR1611 + zoledronic acid Sensitive: C4 – Case Studies
KRAS mutation KRAS mutation	Colorectal Cancer CRC	KRAS mutation KRAS mutation	Colorectal Cancer CRC	CBC9106 Sensitive: C4 – Case Studies	CBC9106 Sensitive: C4 – Case Studies
KRAS mutation KRAS mutation	Cholangiocarcinoma Cholangiocarcinoma	KRAS mutation KRAS mutation	Cholangiocarcinoma Cholangiocarcinoma	trametinib + pazopanib Sensitive: C4 – Case Studies	trametinib + pazopanib Sensitive: C4 – Case Studies